Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis.
Klineova S, Farber R, Saiote C, Farrell C, Delman BN, Tanenbaum LN, Friedman J, Inglese M, Lublin FD, Krieger S. Klineova S, et al. Among authors: farber r. Mult Scler J Exp Transl Clin. 2016 Jun 23;2:2055217316655365. doi: 10.1177/2055217316655365. eCollection 2016 Jan-Dec. Mult Scler J Exp Transl Clin. 2016. PMID: 28607731 Free PMC article.
Emergency Department visits before the diagnosis of MS.
Farber R, Hannigan C, Alcauskas M, Krieger S. Farber R, et al. Mult Scler Relat Disord. 2014 May;3(3):350-4. doi: 10.1016/j.msard.2013.11.004. Epub 2013 Dec 1. Mult Scler Relat Disord. 2014. PMID: 25876472
Objective and subjective measures of dalfampridine efficacy in clinical practice.
Klineova S, Farber R, Friedman J, Farrell C, Lublin FD, Krieger S. Klineova S, et al. Among authors: farber r. Mult Scler J Exp Transl Clin. 2018 Jul 9;4(3):2055217318786742. doi: 10.1177/2055217318786742. eCollection 2018 Jul-Sep. Mult Scler J Exp Transl Clin. 2018. PMID: 30090641 Free PMC article.
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses.
Epstein SE, Levin S, Onomichi K, Langston C, Yeshokumar A, Fabian M, Sand IK, Klineova S, Lublin F, Dykstra K, Xia Z, De Jager P, Levine L, Farber R, Riley C, Vargas WS. Epstein SE, et al. Among authors: farber r. Mult Scler Relat Disord. 2021 Nov;56:103229. doi: 10.1016/j.msard.2021.103229. Epub 2021 Aug 28. Mult Scler Relat Disord. 2021. PMID: 34479112 Free PMC article.
Fatal COVID-19 in an MS patient on natalizumab: A case report.
Rimmer K, Farber R, Thakur K, Braverman G, Podolsky D, Sutherland L, Migliore C, Ryu YK, Levin S, De Jager PL, Vargas W, Levine L, Riley CS. Rimmer K, et al. Among authors: farber r. Mult Scler J Exp Transl Clin. 2020 Aug 10;6(3):2055217320942931. doi: 10.1177/2055217320942931. eCollection 2020 Jul-Sep. Mult Scler J Exp Transl Clin. 2020. PMID: 32850133 Free PMC article.
Evaluation of ocrelizumab in older progressive multiple sclerosis patients.
Epstein S, Fong KT, De Jager PL, Levine L, Riley C, Wesley S, Vargas WS, Farber R. Epstein S, et al. Among authors: farber r. Mult Scler Relat Disord. 2021 Oct;55:103171. doi: 10.1016/j.msard.2021.103171. Epub 2021 Jul 25. Mult Scler Relat Disord. 2021. PMID: 34329872
216 results